Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study identified five FDA-approved drugs—cepharantine, clofazimine, metergoline, imatinib, and efloxate—as potential candidates for repurposing to interfere with viral entry in COVID-19 treatment.

This study identified five FDA-approved drugs, including cepharantine and clofazimine, as potential COVID-19 therapies through in silico and in vitro screening targeting viral entry mechanisms.

This study found that two eco-friendly analytical methods for quantifying Finasteride and Tadalafil in a new dosage form were effective, green, and suitable for quality control.

This study introduced and validated new spectrophotometric methods to simultaneously determine finasteride and tadalafil in Entadfi™ capsules with high sensitivity and without interference from excipients.

This study introduces three spectrophotometric techniques for accurately determining finasteride and tadalafil in their combined pharmaceutical form, demonstrating their sustainability, sensitivity, and suitability for quality assurance, alongside a dissolution study following FDA guidelines.

This study used computational methods to identify pranlukast and mirabegron as promising candidates for repurposing against diabetes due to their good binding interactions with the DPP-IV target.

This source reports that scalp cooling is currently the only safe and FDA-cleared method to potentially reduce chemotherapy-induced hair loss, with about a 50% chance of maintaining sufficient hair to avoid needing a wig.

This review reports that while current treatments for non-scarring alopecia, like minoxidil and finasteride, have limited efficacy due to side effects, natural remedies may offer more effective management with potentially fewer side effects, though their varying safety profiles call for further investigation.

This review concluded that FDA-cleared low-level laser therapy devices are safe and effective for patients with male and female pattern hair loss who do not respond to or tolerate standard treatments.

This chapter reviews the potential applications of genetic engineering in hair growth research and development but provides no new experimental results, emphasizing the need for innovative approaches in the field.

This study highlights that while there are no FDA- or ANVISA-approved treatments for children with alopecia areata, JAK inhibitors are emerging as a promising therapeutic option for this population.

This review discusses methotrexate's use in dermatology and its mechanisms, pharmacokinetics, dosing, side effects, interactions, and emphasizes the need for further research into optimizing therapy and predicting adverse events.

This study reviewed existing methods to prevent chemotherapy-induced hair loss, highlighting FDA-approved scalp cooling as currently the most effective yet still insufficient solution and noting the need for more reliable treatments to better support cancer patients.

This article reviews current diagnostic methods and treatments for hair loss, including FDA-approved drugs and surgical options, but reports no new research findings.

This article reviews 12 newly approved drugs with pediatric indications from 2001, discussing their clinical importance for general pediatricians, but reports no new clinical results.

This article reviews the role of Platelet Rich Plasma in cosmetic dermatology and discusses a new method for storing PRP for personalized home use without reporting clinical outcomes.

This source reviews alopecia areata, highlighting its epidemiology, immune-related causes, diagnostic methods, and the shift in treatment with JAK inhibitors like baricitinib and ritlecitinib, marking the first disease-modifying options for this hair loss condition.

The document discusses male and female pattern hair loss, its diagnosis methods, FDA-approved treatments like finasteride and minoxidil, their side effects, and the role of lifestyle changes.

In this review, the authors explored current and novel treatment options for androgenetic alopecia, noting both FDA-approved pharmacologic treatments like Minoxidil and Finasteride and various non-pharmacologic and surgical methods, including hair transplantation and scalp micro-pigmentation.

This review discusses current and emerging treatments for androgenic alopecia, noting that minoxidil and finasteride are the only FDA-approved options, while other methods lack comparable evidence of efficacy.

Lasers in hair transplantation show promise but are not yet standard, with current methods causing some side effects and needles still being preferred for creating recipient sites.

This article discusses recent advancements in treatments for psoriasis, including new drug approvals and innovative therapeutic approaches, but reports no new clinical results.

In this study, the researchers reviewed psychiatric drugs approved between 2002 and 2022 to analyze trends in drug repurposing, finding an increased application of repurposing methods, especially through fixed-dose combinations, and highlighting technologies like SmartCube® to predict efficacy from animal models.

This review discusses techniques for harvesting follicular units, medical treatments for androgenetic alopecia, and potential future advancements in hair restoration therapy, but it reports no new clinical results.

In this study, a patient with clinically amyopathic dermatomyositis experienced persistent skin issues despite treatment, highlighting questions about type I interferon's role in skin disorders and potential IFN-targeted therapies for cutaneous lupus erythematosus and dermatomyositis.

In this study, researchers used a computational drug repurposing approach to identify FDA-approved drugs Dutasteride and Solifenacin as potential inhibitors of Listeria monocytogenes via binding to the virulence factor regulator PrfA, suggesting they may offer new treatment strategies against multi-drug resistant strains.

This summary from Annals for Educators discusses educational materials on a wide range of topics including methotrexate's adverse effects, therapies for cannabis use disorder, the Hamman sign in physical examination, emotional challenges in medical practice, and renal treatments in lupus nephritis, without providing new clinical results.

This study reviewed treatments for chemotherapy-induced hair loss, finding that scalp cooling is FDA-approved for prevention, while minoxidil and bimatoprost may aid post-chemotherapy regrowth. The authors emphasized tailored therapies and the potential utility of tools like trichoscopy and trichogram.

In this study, researchers used computational modeling and virtual screening to identify two FDA-approved drugs, Tadalafil and Finasteride, that may effectively inhibit key proteins involved in melanoma progression, suggesting potential for new therapeutic strategies against aggressive melanoma.

This article reviews various hair growth and hair loss treatments, noting limited new developments since FDA-approved drugs but highlights recent cosmetic surgery and potential cell-based therapies; it reports no original findings.